Clinical Trial Update: Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria [Phase 3]

View source ↗

Summary

Phase 3 study comparing ADL-018 with XOLAIR (Omalizumab) in adults with Chronic Idiopathic Urticaria has completed. The trial evaluated efficacy, safety, and im…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Urticaria

Drugs mentioned

• ADL-018
• Xolair (omalizumab)

Snippet

Sponsor: Kashiv BioSciences, LLC | Conditions: Chronic Idiopathic Urticaria | Phase 3 | Status: COMPLETED